Hyping HPV

Human papillomavirus is a sexually-transmitted virus with more than 100 subtypes. Although most infections cause no symptoms and resolute spontaneously, in some cases they can result in precancerous lesions.

In 2006, the FDA approved a new HPV vaccine for 9 to 26-year-old women. The vaccine protects against 4 of the 100 strains of HPV. Another HPV vaccine, produced by a U.K. manufacturer, is also available in many parts of the world.

Young teenage girls have no risk of dying from cervical cancer, but they gamble with permanently disabling autoimmune or degenerative disorders, or death, following their HPV vaccines:

The present study provides epidemiological evidence supporting a significant relationship between HPV4 vaccine administration and serious autoimmune adverse events.

For example, women diagnosed with systemic lupus erythematosus, a serious autoimmune disease, were 5 times more likely that controls to have received the HPV vaccine (odds ratio, OR=5.3).

Women diagnosed with alopecia (OR=8.3), gastroenteritis (OR=4.6), vasculitis (OR=4.0), and central nervous system conditions (OR=1.8) were also significantly more likely than controls to have received the HPV vaccine.

Based on the current data, a causal link between HPV vaccination and onset or relapse of systemic lupus erythematosus is plausible.

Death after Quadrivalent Human Papillomavirus Vaccination: Causal or Coincidental? (pdf)

Our study suggests that HPV vaccines containing HPV-16L1 antigens pose an inherent risk for triggering potentially fatal auto-immune vasulopathies.

The HPV vaccine has been linked to chronic pain, fatigue and nervous system damage:

Adverse reactions appear to be more frequent after HPV vaccination when compared to other type of immunizations. Clinicians should be aware of the possible association between HPV vaccination and the development of these difficult to diagnose painful dysautonomic syndromes.

Chronic fatigue syndrome/myalgic encephalomyelitis may be a suitable diagnosis for patients with severe and persistent suspected side effects to the quadrivalent HPV vaccine. (pdf)

Damage to the autonomic nervous system has been consistently reported after HPV vaccination, causing muscle weakness, pain, fatigue, and menstrual problems.

A relatively high incidence of chronic limb pain, frequently complicated by violent, tremulous involuntary movements, has been noted in Japanese girls following HPV vaccination.

Some girls develop premature ovarian insufficiency after HPV vaccination, which may affect childbearing. Current HPV vaccine safety research is inadequate to determine ovarian safety.

Further work is urgently needed to elucidate the potential for a causal link between the vaccine and circulatory abnormalities and to establish targeted treatment options for the affected patients.

The HPV vaccine may cause autoimmunity and ovarian failure:

We documented here the evidence of the potential of the HPV vaccine to trigger a life-disabling autoimmune condition. The increasing number of similar reports of post HPV vaccine-linked autoimmunity and the uncertainty of long-term clinical benefits of HPV vaccination are a matter of public health that warrants further rigorous inquiry.

Clinical trials and marketing tactics by the HPV vaccine manufacturer may not be trustworthy:

The poor design of existing vaccine safety and efficacy trials may be reflective of the fact that in the past two decades the pharmaceutical industry has gained unprecedented control over the evaluation of its own products.

Coercive tactics such as vaccine mandates that are supported solely by vaccine manufactures' own data is unacceptable.

The HPV vaccine manufacturer aggressively lobbied legislators to mandate their vaccine for school entry, drafted the legislation, provided the science, and made financial contributions to lawmakers.

There is no significant evidence showing that HPV vaccination can prevent cervical cancer, and the long-term benefits are based on assumptions, not reliable research data:

Current worldwide HPV immunization practices appear to be neither justified by long-term health benefits nor economically viable, nor is there any evidence that HPV vaccination (even if proven effective against cervical cancer) would reduce the rate of cervical cancer beyond what Pap screening has already achieved.

The FDA licensed the HPV vaccine based on safety and efficacy studies that were designed, sponsored and conducted by the vaccine manufacturer.

We find that HPV vaccine clinical trials design, and data interpretation of both efficacy and safety outcomes, were largely inadequate. Additionally, we note evidence of selective reporting of results from clinical trials. Given this, the widespread optimism regarding HPV vaccines long-term benefits appears to rest on a number of unproven assumptions and significant misinterpretation of available data.

Likewise, the notion that HPV vaccines have an impressive safety profile is only supported by highly flawed design of safety trials and is contrary to accumulating evidence from vaccine safety surveillance databases and case reports which continue to link HPV vaccination to serious adverse outcomes (including death and permanent disabilities).

We thus conclude that further reduction of cervical cancers might be best achieved by optimizing cervical screening (which carries no such risks) and targeting other factors of the disease rather than by the reliance on vaccines with questionable efficacy and safety profiles.

HPV vaccine safety and efficacy claims are at odds with factual evidence:

Whilst 12-year-old preadolescents are at zero risk of dying from cervical cancer, they are faced with a risk of death and a permanently disabling lifelong autoimmune or neurodegenerative condition from a vaccine that thus far has not prevented a single case of cervical cancer, let alone cervical cancer death.